Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891761897> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W2891761897 endingPage "e21685" @default.
- W2891761897 startingPage "e21685" @default.
- W2891761897 abstract "e21685 Background: Chemotherapy-induced nausea and vomiting (CINV) is a distressing symptom of cancer treatment; in lung cancer, carboplatin is commonly used. In a post hoc analysis, we explored prevention of CINV in lung cancer patients with a single-day triple-antiemetic fosaprepitant (FA) regimen compared with a standard 3-day control regimen. Methods: This was a phase 3, global, randomized, double-blind, parallel-group study in adults scheduled to receive an intravenous (IV) dose of ≥1 moderately emetogenic chemotherapy (MEC) on treatment day 1 (NCT01594749). Subjects were randomly assigned 1:1 to a control or FA regimen. The control regimen consisted of 8 mg oral ondansetron, 20 mg dexamethasone, and IV saline as placebo before the first dose of MEC on day 1, and 8 mg oral ondansetron 8 hours after the first dose and every 12 hours on days 2 and 3. The FA regimen consisted of the same dose of oral ondansetron on day 1, along with 12 mg dexamethasone and a single dose of 150 mg IV FA before the first dose of MEC on day 1, with no additional prophylactic antiemetic beyond day 1. The primary end point was complete response (CR; no vomiting or rescue medication) in the delayed phase (25-120 hours). Results: Overall, 1000 subjects were included in the intention-to-treat population (FA: n = 502; control: n = 498). The primary end point was met ( P < 0.001; FA vs control). In a subset of 254 subjects with lung cancer (71% male), 129 in FA regimen and 125 in control regimen, most (98%) received carboplatin-based chemotherapy. CR in the delayed phase was achieved by 80.6% in the FA group and 74.4% in the control group (difference, 6.2%). More subjects had no vomiting episodes in the FA (85.3%) vs control (78.4%) groups within the delayed phase (difference, 6.9%), and overall time-to-first vomiting episode was longer for subjects in the FA group. Adverse events (AEs) were similar between groups: overall AEs occurred in 57.7% and 54.8%, and serious AEs occurred in 12.3% and 12.1% in the FA and control groups, respectively. No serious AEs were considered related to study medication. Conclusions: A single-day IV FA regimen is effective for preventing CINV in patients with lung cancer receiving carboplatin. Clinical trial information: NCT01594749." @default.
- W2891761897 created "2018-09-27" @default.
- W2891761897 creator A5003050822 @default.
- W2891761897 creator A5013834421 @default.
- W2891761897 creator A5038564366 @default.
- W2891761897 creator A5043177871 @default.
- W2891761897 creator A5044629794 @default.
- W2891761897 creator A5045288167 @default.
- W2891761897 creator A5059391185 @default.
- W2891761897 creator A5078590370 @default.
- W2891761897 creator A5090892595 @default.
- W2891761897 date "2017-05-20" @default.
- W2891761897 modified "2023-09-23" @default.
- W2891761897 title "Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in lung cancer patients receiving carboplatin-based therapies." @default.
- W2891761897 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e21685" @default.
- W2891761897 hasPublicationYear "2017" @default.
- W2891761897 type Work @default.
- W2891761897 sameAs 2891761897 @default.
- W2891761897 citedByCount "0" @default.
- W2891761897 crossrefType "journal-article" @default.
- W2891761897 hasAuthorship W2891761897A5003050822 @default.
- W2891761897 hasAuthorship W2891761897A5013834421 @default.
- W2891761897 hasAuthorship W2891761897A5038564366 @default.
- W2891761897 hasAuthorship W2891761897A5043177871 @default.
- W2891761897 hasAuthorship W2891761897A5044629794 @default.
- W2891761897 hasAuthorship W2891761897A5045288167 @default.
- W2891761897 hasAuthorship W2891761897A5059391185 @default.
- W2891761897 hasAuthorship W2891761897A5078590370 @default.
- W2891761897 hasAuthorship W2891761897A5090892595 @default.
- W2891761897 hasConcept C126322002 @default.
- W2891761897 hasConcept C2776256026 @default.
- W2891761897 hasConcept C2776694085 @default.
- W2891761897 hasConcept C2777170512 @default.
- W2891761897 hasConcept C2778239845 @default.
- W2891761897 hasConcept C2778336483 @default.
- W2891761897 hasConcept C2779924295 @default.
- W2891761897 hasConcept C2780401358 @default.
- W2891761897 hasConcept C2780580376 @default.
- W2891761897 hasConcept C2780852908 @default.
- W2891761897 hasConcept C2780884295 @default.
- W2891761897 hasConcept C2781413609 @default.
- W2891761897 hasConcept C2781451048 @default.
- W2891761897 hasConcept C2908647359 @default.
- W2891761897 hasConcept C42219234 @default.
- W2891761897 hasConcept C71924100 @default.
- W2891761897 hasConcept C90924648 @default.
- W2891761897 hasConcept C99454951 @default.
- W2891761897 hasConceptScore W2891761897C126322002 @default.
- W2891761897 hasConceptScore W2891761897C2776256026 @default.
- W2891761897 hasConceptScore W2891761897C2776694085 @default.
- W2891761897 hasConceptScore W2891761897C2777170512 @default.
- W2891761897 hasConceptScore W2891761897C2778239845 @default.
- W2891761897 hasConceptScore W2891761897C2778336483 @default.
- W2891761897 hasConceptScore W2891761897C2779924295 @default.
- W2891761897 hasConceptScore W2891761897C2780401358 @default.
- W2891761897 hasConceptScore W2891761897C2780580376 @default.
- W2891761897 hasConceptScore W2891761897C2780852908 @default.
- W2891761897 hasConceptScore W2891761897C2780884295 @default.
- W2891761897 hasConceptScore W2891761897C2781413609 @default.
- W2891761897 hasConceptScore W2891761897C2781451048 @default.
- W2891761897 hasConceptScore W2891761897C2908647359 @default.
- W2891761897 hasConceptScore W2891761897C42219234 @default.
- W2891761897 hasConceptScore W2891761897C71924100 @default.
- W2891761897 hasConceptScore W2891761897C90924648 @default.
- W2891761897 hasConceptScore W2891761897C99454951 @default.
- W2891761897 hasIssue "15_suppl" @default.
- W2891761897 hasLocation W28917618971 @default.
- W2891761897 hasOpenAccess W2891761897 @default.
- W2891761897 hasPrimaryLocation W28917618971 @default.
- W2891761897 hasRelatedWork W1824703102 @default.
- W2891761897 hasRelatedWork W2020302560 @default.
- W2891761897 hasRelatedWork W2057593650 @default.
- W2891761897 hasRelatedWork W2059310179 @default.
- W2891761897 hasRelatedWork W2059421488 @default.
- W2891761897 hasRelatedWork W2245662675 @default.
- W2891761897 hasRelatedWork W2376134526 @default.
- W2891761897 hasRelatedWork W2563903067 @default.
- W2891761897 hasRelatedWork W2578694077 @default.
- W2891761897 hasRelatedWork W4241369461 @default.
- W2891761897 hasVolume "35" @default.
- W2891761897 isParatext "false" @default.
- W2891761897 isRetracted "false" @default.
- W2891761897 magId "2891761897" @default.
- W2891761897 workType "article" @default.